Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
RCT
ACE Report #12274
Ace Report Cover General Orthopaedics

Similar Outcomes and Prognosis between Osteoblastic Cell vs Standard Therapy in Patients with ONFH


Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Did Osteoblastic Cell Therapy Improve the Prognosis of Pre-fracture Osteonecrosis of the Femoral Head? A Randomized, Controlled Trial

Clin Orthop Relat Res. 2020 Jun;478(6):1307-1315.

Contributing Authors: JP Hauzeur C Lechanteur E Baudoux V De Maertelaer S Pather R Katz M Malaise J Ino Y Beguin

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Fifty-nine patients were randomized into receiving bone marrow aspirate concentrate (BMAC) or osteoblastic cell therapy for the treatment of nontraumatic osteonecrosis of the femoral head (ONFH). The primary outcomes included fracture progression as well as improvement in pain and functionality, which were all measured at 36 months. The secondary outcomes consisted of the proportion of hips conver...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.